146 related articles for article (PubMed ID: 26133029)
1. Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity.
Gadd AJ; Greco F; Cobb AJ; Edwards AD
Bioconjug Chem; 2015 Aug; 26(8):1743-52. PubMed ID: 26133029
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand.
Wu CC; Hayashi T; Takabayashi K; Sabet M; Smee DF; Guiney DD; Cottam HB; Carson DA
Proc Natl Acad Sci U S A; 2007 Mar; 104(10):3990-5. PubMed ID: 17360465
[TBL] [Abstract][Full Text] [Related]
3. UC-1V150, a potent TLR7 agonist capable of activating macrophages and potentiating mAb-mediated target cell deletion.
Dahal LN; Gadd A; Edwards AD; Cragg MS; Beers SA
Scand J Immunol; 2018 Jun; 87(6):e12666. PubMed ID: 29667229
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides.
Shinchi H; Crain B; Yao S; Chan M; Zhang SS; Ahmadiiveli A; Suda Y; Hayashi T; Cottam HB; Carson DA
Bioconjug Chem; 2015 Aug; 26(8):1713-23. PubMed ID: 26193334
[TBL] [Abstract][Full Text] [Related]
5. Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue.
Corogeanu D; Zaki K; Beavil AJ; Arnold JN; Diebold SS
PLoS One; 2023; 18(3):e0282831. PubMed ID: 36913398
[TBL] [Abstract][Full Text] [Related]
6. Conjugation of a Small-Molecule TLR7 Agonist to Silica Nanoshells Enhances Adjuvant Activity.
Huang CH; Mendez N; Echeagaray OH; Weeks J; Wang J; Vallez CN; Gude N; Trogler WC; Carson DA; Hayashi T; Kummel AC
ACS Appl Mater Interfaces; 2019 Jul; 11(30):26637-26647. PubMed ID: 31276378
[TBL] [Abstract][Full Text] [Related]
7. Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model.
Vecchi S; Bufali S; Uno T; Wu T; Arcidiacono L; Filippini S; Rigat F; O'Hagan D
Eur J Pharm Biopharm; 2014 Jul; 87(2):310-7. PubMed ID: 24434202
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Hamm S; Rath S; Michel S; Baumgartner R
J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
[TBL] [Abstract][Full Text] [Related]
9. Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects.
Wang XD; Gao NN; Diao YW; Liu Y; Gao D; Li W; Wan YY; Zhong JJ; Jin GY
World J Gastroenterol; 2015 Jul; 21(26):8052-60. PubMed ID: 26185376
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and immunostimulatory activity of sugar-conjugated TLR7 ligands.
Baba A; Wakao M; Shinchi H; Chan M; Hayashi T; Yao S; Cottam HB; Carson DA; Suda Y
Bioorg Med Chem Lett; 2020 Feb; 30(3):126840. PubMed ID: 31864800
[TBL] [Abstract][Full Text] [Related]
11. High potency of lipid conjugated TLR7 agonist requires nanoparticulate or liposomal formulation.
Gadd AJR; Castelletto V; Kabova E; Shankland K; Perrie Y; Hamley I; Cobb AJA; Greco F; Edwards AD
Eur J Pharm Sci; 2018 Oct; 123():268-276. PubMed ID: 30048801
[TBL] [Abstract][Full Text] [Related]
12. Bacille Calmette-Guerin can induce cellular apoptosis of urothelial cancer directly through toll-like receptor 7 activation.
Yu DS; Wu CL; Ping SY; Keng C; Shen KH
Kaohsiung J Med Sci; 2015 Aug; 31(8):391-7. PubMed ID: 26228277
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and immunoregulatory activities of conjugates of a Toll-like receptor 7 inert ligand.
Gao D; Liu Y; Li W; Zhong F; Zhang X; Diao Y; Gao N; Wang X; Jiang W; Jin G
Bioorg Med Chem Lett; 2014 Dec; 24(24):5792-5795. PubMed ID: 25453821
[TBL] [Abstract][Full Text] [Related]
14. Gold Nanoparticles Coimmobilized with Small Molecule Toll-Like Receptor 7 Ligand and α-Mannose as Adjuvants.
Shinchi H; Yamaguchi T; Moroishi T; Yuki M; Wakao M; Cottam HB; Hayashi T; Carson DA; Suda Y
Bioconjug Chem; 2019 Nov; 30(11):2811-2821. PubMed ID: 31560198
[TBL] [Abstract][Full Text] [Related]
15. Generation of tumor-targeted antibody-CpG conjugates.
Li Z; Jang JK; Lechner MG; Hu P; Khawli L; Scannell CA; Epstein AL
J Immunol Methods; 2013 Mar; 389(1-2):45-51. PubMed ID: 23279945
[TBL] [Abstract][Full Text] [Related]
16. Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy.
Butchar JP; Mehta P; Justiniano SE; Guenterberg KD; Kondadasula SV; Mo X; Chemudupati M; Kanneganti TD; Amer A; Muthusamy N; Jarjoura D; Marsh CB; Carson WE; Byrd JC; Tridandapani S
Clin Cancer Res; 2010 Apr; 16(7):2065-75. PubMed ID: 20332325
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies.
Lan T; Dai M; Wang D; Zhu FG; Kandimalla ER; Agrawal S
J Med Chem; 2009 Nov; 52(21):6871-9. PubMed ID: 19824640
[TBL] [Abstract][Full Text] [Related]
18. TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy.
Kim H; Khanna V; Kucaba TA; Zhang W; Sehgal D; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2020 Jun; 17(6):2109-2124. PubMed ID: 32383885
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates.
Chan M; Hayashi T; Kuy CS; Gray CS; Wu CC; Corr M; Wrasidlo W; Cottam HB; Carson DA
Bioconjug Chem; 2009 Jun; 20(6):1194-200. PubMed ID: 19445505
[TBL] [Abstract][Full Text] [Related]
20. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
